Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs

1. A method of treating cancer in a human, wherein the cancer expresses epidermal growth factor receptor (EGFR) and ErbB2, comprising administering to the human therapeutically effective amounts of an ErbB2 antibody which blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB-12697) to ErbB2, and an EGFR-targeted drug, wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer.

2. The method of claim 1 wherein the ErbB2 antibody blocks ligand activation of an ErbB receptor.

3. The method of claim 1 wherein the cancer is characterized by excessive activation of EGFR.

4. The method of claim 1 wherein the ErbB2 antibody blocks TGF-α activation of mitogen-activated protein kinase (MAPK).

5. The method of claim 1 wherein the cancer is not characterized by overexpression of ErbB2 receptor.

6. The method of claim 1 wherein the EGFR-targeted drug comprises an antibody that binds to EGFR.

7. The method of claim 6 wherein the EGFR antibody is selected from the group consisting of MAb 579 (ATCC CRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb 528 (ATCC CRL 8509), C225, reshaped human 225 (H225), an antibody that binds type II mutant EGFR, and a human antibody that binds EGFR.

8. The method of claim 1 wherein the EGFR-targeted drug comprises a small molecule that binds to EGFR.

9. The method of claim 8 wherein the small molecule is selected from the group consisting of ZD1839, CP-358774, and AG1478.

10. The method of claim 1 wherein the cancer is non small cell lung cancer (NSCLC).

11. The method of claim 1 wherein the ErbB2 antibody comprises a humanized form of monoclonal antibody 2C4 (ATCC HB-12697).

12. The method of claim 1 wherein the ErbB2 antibody comprises variable light (V L ) and variable heavy (V H ) sequences of SEQ ID Nos. 3 and 4, respectively.

13. The method of claim 12 wherein the V L and V H sequences are fused to human light and heavy IgG1 (non-A allotype) constant region sequences.

14. The method of claim 1 wherein the ErbB2 antibody is not conjugated with a cytotoxic agent.

15. The method of claim 1 comprising administering at least one dose of the ErbB2 antibody to the human in an amount from about 0.5 mg/kg to about 10 mg/kg.

16. The method of claim 15 comprising administering the dose about every three weeks.

17. The method of claim 1 wherein the ErbB2 antibody is about 50-100% more effective than 4D5 (ATCC CRL 10463) at blocking formation of an ErbB2 hetero-oligomer.

18. The method of claim 1 wherein the cancer is pancreatic cancer.

19. The method of claim 1 wherein the cancer is colon cancer.

20. The method of claim 1 wherein the cancer is rectal cancer.

21. The method of claim 1 wherein the cancer is colorectal cancer.

22. The method of claim 1 wherein the cancer is head and neck cancer.

23. The method of claim 1 wherein the cancer is ovarian cancer.

24. A method of treating cancer in a human comprising administering to the human therapeutically effective amounts of rhuMAb 2C4, and an EGFR-targeted drug selected from the group consisting of C225, ZD1839, and CP-358774, wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer.

25. The method of claim 24 wherein the cancer is NSCLC.

26. A method of treating cancer in a human, wherein the cancer is selected from the group consisting of non small cell lung cancer (NSCLC), pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, head and neck cancer, and ovarian cancer, endometrial cancer, and hepatocellular cancer, comprising administering to the human therapeutically effective amounts of an EGFR-targeted drug, and an antibody comprising variable light (V L ) and variable heavy (V H ) sequences of SEQ ID Nos. 3 and 4, respectively.

27. The method of claim 26 wherein the cancer is NSCLC.

28. The method of claim 26 wherein the V L and V H sequences are fused to human light and heavy IgG1 (non-A allotype) constant region sequences.